CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Aura Biosciences, Inc.

AURA
$627MSmall Cap

Next catalyst

Phase 2November 2026

AU-011

Eye Cancer

Get an email about AURA's next catalysts

Track Aura Biosciences (AURA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline

Catalyst Timeline

2 upcoming, 4 past

Phase 2Next

AU-011 Phase 2 Est. Readout

November 2026~AU-01124

Primary completion for AU-011 trial (NCT06643884) in Eye Cancer

Source
Phase 3

Bel-sar Phase 3 Est. Readout (CoMpass)

Q4 2027~QBel-sar108

Primary completion for Bel-sar trial (NCT06007690) in Choroidal Melanoma

Source

How AURA's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)πŸ‡ΊπŸ‡ΈNorth AmericaBOSTON106 employees
Drug Pipeline

Frequently asked questions

What is in Aura Biosciences, Inc.'s drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in Aura Biosciences, Inc.'s (AURA) pipeline across Phase 3, Phase 2. Its lead program is Bel-sar (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Aura Biosciences, Inc.'s next FDA catalyst?β†’

Aura Biosciences, Inc.'s (AURA) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track AURA biotech catalysts?β†’

Add AURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aura Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply